Breathe Well Live Well
|
German firm Boehringer Ingelheim's patent for asthma drug revoked
Economic Times MUMBAI: India's Patent Office has revoked a patent on asthma drug, Spiriva (tiotropium bromide monohydrate) held by German major Boehringer Ingelheim on an opposition filed by generic company, Cipla. The patent was revoked on grounds that it lacks … |
View full post on asthma – Google News
|
German co's patent for asthma drug revoked
Times of India MUMBAI: India's Patent Office has revoked a patent on asthma drug, Spiriva (tiotropium bromide monohydrate) held by German major Boehringer Ingelheim on an opposition filed by generic company, Cipla. The patent was revoked on grounds that it lacks … |
View full post on asthma – Google News
|
Asthma Drug Xolair Linked to Severe Brain, Heart Issues, Pharmaceutical …
Business Wire (press release) DALLAS–(BUSINESS WIRE)–Xolair, a drug used to treat allergic asthma in adults and children 12 years and older, has been linked to significant health issues such as mini-strokes, heart attacks and blood clots, the national law firm of Baron and Budd … |
View full post on asthma – Google News
EurekAlert |
Investigational drug can reduce asthma flareups
Medical Xpress An investigational drug appears to cut the risk of severe asthma attacks in half for patients who have difficulty controlling the disorder with standard medications, according to results from two multicenter clinical trials. Most Popular Stories |
View full post on asthma – Google News
HSPH News |
Newly found genes affecting allergies and asthma could provide new drug targets
HSPH News Boston, MA – Allergies affect 30% of people around the world and asthma afflicts 10% of all children. Now, a new study has uncovered more than 30 genes that have strong effects on allergies, asthma, and Immunoglobulin E (IgE)—an antibody that triggers … |
View full post on asthma – Google News
Drug Discovery & Development |
Study Highlights Drug Targets for Allergies, Asthma
Drug Discovery & Development Illustration of a DNA molecule that is methylated at two sites in the centre. Source: (Max Planck Institute for Informatics) Asthma affects one child in 10 in the UK, and allergies may affect one third of the population. The new findings could lead to … Epigenetic study highlights drug targets for allergies and asthma Asthma cure a step closer after scientists discover 34 genes that make people … Researchers discover promising targets for treating allergies and asthma |
View full post on asthma – Google News
Yahoo News UK |
Public Release: 18-Feb-2015 Epigenetic study highlights drug targets for …
EurekAlert (press release) Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs. Asthma affects one child in 10 in the UK, and allergies may affect one third of the population. The new findings … Epigenetic study highlights drug targets for allergies and asthma Researchers discover promising targets for treating allergies and asthma Gene research shows promise for asthma treatment |
View full post on asthma – Google News
Laboratory Talk |
Epigenetic study highlights drug targets for allergies and asthma
Medical Xpress The researchers analysed white blood cells from families with asthma in the UK to see whether methylation levels in certain parts of the genome were correlated with the level of IgE in the blood. To be sure of their results, the researchers tested … Public Release: 18-Feb-2015 Epigenetic study highlights drug targets for … Researchers discover promising targets for treating allergies and asthma New hope for asthma and allergy sufferers |
View full post on asthma – Google News
Business Insider |
AstraZeneca's patent on asthma drug invalidated by U.S. court
Business Insider NEW YORK (Reuters) – A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version. Actavis Plc said that the U.S. District … AstraZeneca plc (ADR) Patent On Asthma Drug Declared Invalid By US Court AstraZeneca loses its US patent rights for asthma drug Pulmicort Respules |
View full post on asthma – Google News
Reuters |
AstraZeneca's patent on asthma drug invalidated by US court
Reuters NEW YORK (Reuters) – A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version. Actavis Plc said that the U.S. District … Actavis launches Pulmicort Respules generic on AZ legal loss |
View full post on asthma – Google News